Published :
Tables : 43
Figures : 41
Category : Healthcare
No. of Pages : 210
Report Code : HC-1066
Acute myeloid leukemia market is envisioned to value over CAGR of over 12% during the forecast period of 2022-2028. Acute Myeloid Leukemia (AML) is a cancer of myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid build-up of abnormal white blood cells causes interference in the production of normal blood cells. Acute Myeloid Leukemia has a propensity to increase towards age. Replacement of bone marrow with cancer cells causes a drop in blood constituents such as red blood cells, platelets, white blood cells, etc. This causes symptoms such as fatigue, breathlessness, easy bruising and bleeding. The market driving factors for acute myeloid Leukemia are a rise in risk factors such as carcinogens, bold disorders, and genetics, etc. According to the American Cancer Society, about 21,450 newly diagnosed cases are registered with a mortality rate of 50% in 2018. It mostly affects the adult population with a 5-year survival rate of 27%. Rapidly evolving scientific understanding of etiology led to the development of new therapeutic approaches for better management of AML. Further, increasing research activities led to the inclusion of immunotherapies in clinical practice and increased the life expectancy of AML patients. They are huge demand for effective management of disease due to highly unmet medical need and it offers monopolistic opportunities for manufacture. Further, supportive regulatory conditions like research incentives & fast approvals boosted the research activities in Acute Myeloid Leukemia area. Further, technological advancements led to the integration of gene therapies in the treatment and create opportunities for innovators. North America market is expected to witness high market share in the global market due to supportive regulatory policies and high per capita healthcare expenditure. It is followed by the European region and it accounts a significant share in the global market due to well-established healthcare systems. Asia-Pacific regions are expected to witness a high market growth rate during the forecast period due to increasing awareness and changing healthcare policies. Latin America and Rest of the world market are expected to account a small fraction of market share due to lack of awareness. Key Market Players include Johnson & Johnson Private Limited, Pfizer Inc. Abbott, AstraZeneca, Bayer, Celgene Corporation, Ambit Biosciences Corporation, Cyclacel Pharmaceuticals Inc. Novartis AG and Sanofi. Acute Myeloid Leukemia Market Segmentation By Drug Class Tyrosine Kinase Inhibitors Hedgehog Pathway Inhibitors Topoisomerase 2 Inhibitors Others By End User Hospital Clinic Others By Region North America Latin America Europe Asia Pacific Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global Acute Myeloid Leukemia Market by Drug Class, by End User and by Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Acute Myeloid Leukemia (AML) is a cancer of myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid build-up of abnormal white blood cells causes interference in the production of normal blood cells. Acute Myeloid Leukemia has a propensity to increase towards age. Replacement of bone marrow with cancer cells causes a drop in blood constituents such as red blood cells, platelets, white blood cells, etc. This causes symptoms such as fatigue, breathlessness, easy bruising and bleeding. The market driving factors for acute myeloid Leukemia are a rise in risk factors such as carcinogens, bold disorders, and genetics, etc.
According to the American Cancer Society, about 21,450 newly diagnosed cases are registered with a mortality rate of 50% in 2018. It mostly affects the adult population with a 5-year survival rate of 27%. Rapidly evolving scientific understanding of etiology led to the development of new therapeutic approaches for better management of AML. Further, increasing research activities led to the inclusion of immunotherapies in clinical practice and increased the life expectancy of AML patients. They are huge demand for effective management of disease due to highly unmet medical need and it offers monopolistic opportunities for manufacture. Further, supportive regulatory conditions like research incentives & fast approvals boosted the research activities in Acute Myeloid Leukemia area. Further, technological advancements led to the integration of gene therapies in the treatment and create opportunities for innovators.
North America market is expected to witness high market share in the global market due to supportive regulatory policies and high per capita healthcare expenditure. It is followed by the European region and it accounts a significant share in the global market due to well-established healthcare systems. Asia-Pacific regions are expected to witness a high market growth rate during the forecast period due to increasing awareness and changing healthcare policies. Latin America and Rest of the world market are expected to account a small fraction of market share due to lack of awareness.
Key Market Players include Johnson & Johnson Private Limited, Pfizer Inc. Abbott, AstraZeneca, Bayer, Celgene Corporation, Ambit Biosciences Corporation, Cyclacel Pharmaceuticals Inc. Novartis AG and Sanofi.
Acute Myeloid Leukemia Market Segmentation
By Drug Class
By End User
By Region
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the global Acute Myeloid Leukemia Market by Drug Class, by End User and by Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Acute Myeloid Leukemia Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Acute Myeloid Leukemia Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Acute Myeloid Leukemia Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Acute Myeloid Leukemia Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Acute Myeloid Leukemia Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Tyrosine Kinase Inhibitors 7.2. Hedgehog Pathway Inhibitors 7.3. Topoisomerase 2 Inhibitors 7.4 Others 8. Global Acute Myeloid Leukemia Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Hospital 8.2. Clinic 8.3. Others 9. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2028 10. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2022-2028 11. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2022-2028 12. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 13. Middle East and Africa Market Analysis 2015–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2020 13.2.1. GCC 13.2.2. Israel 13.2.3. South Africa 13.2.4. Rest of MEA 13.3. Market Size (USD Million) Forecast for MEA 2022-2028 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 14.1. Johnson & Johnson Private Limited 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Pfizer Inc. 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Abbott 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. AstraZeneca 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5 Bayer 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6 Celgene Corporation 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. Ambit Biosciences Corporation 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Novartis AG 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. Cyclacel Pharmaceuticals Inc 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10. Sanofi 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 15. Pre and Post COVID-19 Impact 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations 16. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Acute Myeloid Leukemia Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Acute Myeloid Leukemia Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Acute Myeloid Leukemia Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Acute Myeloid Leukemia Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Acute Myeloid Leukemia Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Tyrosine Kinase Inhibitors 7.2. Hedgehog Pathway Inhibitors 7.3. Topoisomerase 2 Inhibitors 7.4 Others 8. Global Acute Myeloid Leukemia Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Hospital 8.2. Clinic 8.3. Others 9. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2028 10. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2022-2028 11. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2022-2028 12. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 13. Middle East and Africa Market Analysis 2015–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2020 13.2.1. GCC 13.2.2. Israel 13.2.3. South Africa 13.2.4. Rest of MEA 13.3. Market Size (USD Million) Forecast for MEA 2022-2028 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 14.1. Johnson & Johnson Private Limited 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Pfizer Inc. 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Abbott 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. AstraZeneca 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5 Bayer 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6 Celgene Corporation 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. Ambit Biosciences Corporation 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Novartis AG 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. Cyclacel Pharmaceuticals Inc 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10. Sanofi 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview
15. Pre and Post COVID-19 Impact 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations
16. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics